INSPIREMD 1/18 DL-0001 (II2) - Cash Flow Conversion Efficiency
Based on the latest financial reports, INSPIREMD 1/18 DL-0001 (II2) has a cash flow conversion efficiency ratio of -0.169x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-9.35 Million ≈ $-10.93 Million USD) by net assets (€55.20 Million ≈ $64.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See II2 equity to assets ratio to measure how much of total assets are equity-financed.
INSPIREMD 1/18 DL-0001 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how INSPIREMD 1/18 DL-0001's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore II2 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
INSPIREMD 1/18 DL-0001 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of INSPIREMD 1/18 DL-0001 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Colorpak Indonesia Tbk
JK:CLPI
|
-0.056x |
|
Hunyvers SA
PA:ALHUN
|
0.032x |
|
Shenzhen Zhongheng Huafa Co Ltd Class B
SHE:200020
|
-0.034x |
|
Cohen & Company Inc
NYSE MKT:COHN
|
-0.312x |
|
Imugene Ltd
AU:IMU
|
-0.620x |
|
Maskapai Reasuransi Indonesia
JK:MREI
|
0.031x |
|
Jian Sin Industrial Co Ltd
TWO:4502
|
0.016x |
|
Asian Hotels (East) Limited
NSE:AHLEAST
|
0.039x |
Annual Cash Flow Conversion Efficiency for INSPIREMD 1/18 DL-0001 (2021–2025)
The table below shows the annual cash flow conversion efficiency of INSPIREMD 1/18 DL-0001 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see II2 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €55.20 Million ≈ $64.54 Million |
€-35.10 Million ≈ $-41.04 Million |
-0.636x | -4.94% |
| 2024-12-31 | €36.09 Million ≈ $42.19 Million |
€-21.87 Million ≈ $-25.57 Million |
-0.606x | -46.17% |
| 2023-12-31 | €39.50 Million ≈ $46.18 Million |
€-16.38 Million ≈ $-19.15 Million |
-0.415x | +53.61% |
| 2022-12-31 | €17.39 Million ≈ $20.33 Million |
€-15.54 Million ≈ $-18.17 Million |
-0.894x | -126.82% |
| 2021-12-31 | €33.53 Million ≈ $39.20 Million |
€-13.21 Million ≈ $-15.44 Million |
-0.394x | -- |
About INSPIREMD 1/18 DL-0001
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard c… Read more